Skip to main content
SpringerLink
Log in

Drugs on the horizon for diabesity

  • Published:
Current Diabetes Reports Aims and scope Submit manuscript

Abstract

The coexistence of type 2 diabetes and obesity presents a complex therapeutic challenge. Future combination tablets may include agents to address diabetes and any accompanying cardiovascular risk factors. Injectable agents that improve glycemic control and facilitate weight loss have recently become available: the soluble amylin analogue pramlintide provides an adjunct to insulin therapy in type 1 and type 2 diabetes, and the incretin mimetic exenatide can enhance prandial insulin release in type 2 diabetes. Orally active inhibitors of the incretin-degrading enzyme dipeptidyl peptidase-IV, agonists of peroxisome proliferator-activated receptor (PPAR)-α and PPAR-γ ("dual PPARs"), and the CB1 cannabinoid receptor inhibitor rimonabant are advanced in clinical development. Many novel antidiabetic and antiobesity compounds are emerging in preclinical development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Shafrir E: Animal models for non-insulin-dependent diabetes. Diabetes Metab Rev 1992, 8:179–208.

    Article  PubMed  CAS  Google Scholar 

  2. Lazar MA: How obesity causes diabetes: not a tall tale. Science 2005, 307:373–375.

    Article  PubMed  CAS  Google Scholar 

  3. Montague CT, O’Rahilly S: The perils of portliness. Causes and consequences of visceral adiposity. Diabetes 2000, 49:883–888.

    Article  PubMed  CAS  Google Scholar 

  4. Maggio CA, Pi-Sunyer FX: Obesity and type 2 diabetes. Endocrinol Metab Clin North Am 2003, 32:805–822.

    Article  PubMed  Google Scholar 

  5. Scheen AJ, Lefebvre PJ: Management of the obese diabetic patient. Diabetes Rev 1999, 7:77–93.

    Google Scholar 

  6. Krentz AJ, Bailey CJ: Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 2005, 65:385–411.

    Article  PubMed  CAS  Google Scholar 

  7. Turner RC, Cull CA, Frighi V, Holman RR: Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. Progressive requirement for multiple therapies (UKPDS 49). JAMA 1999, 281:2005–2012.

    Article  PubMed  CAS  Google Scholar 

  8. Bailey CJ: Whence and whither the fixed-dose combination? Diabetes Vasc Dis Res 2005, 2:51–53.

    Google Scholar 

  9. Garber AJ, Larsen J, Schneider SH, et al.: Simultaneous glyburide/metformin is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes. Diabetes Obes Metab 2003, 4:201–208.

    Article  Google Scholar 

  10. Bailey CJ: Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab 2005, 7:650–667.

    Article  CAS  Google Scholar 

  11. Wald NJ, Law MR: A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003, 326:1419–1423.

    Article  PubMed  CAS  Google Scholar 

  12. Clark A, Nilsson MR: Islet amyloid: a complication of islet dysfunction or an aetiological factor in type 2 diabetes? Diabetologia 2004, 47:157–169.

    Article  PubMed  CAS  Google Scholar 

  13. Weyer C, Maggs DG, Young AA, Kolterman OG: Amylin replacement with pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes mellitus: a physiological approach toward improved metabolic control. Curr Pharm Des 2001, 7:1353–1373. Comprehensive review of the scientific rationales for use of pramlintide as an adjunct to insulin therapy in type 1 and type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  14. Thompson RG, Peterson J, Gottlieb A, Mullane J: Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial. Diabetes 1997, 46:632–636.

    Article  PubMed  CAS  Google Scholar 

  15. Weyer C, Gottlieb A, Kim DD, et al.: Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes. Diabetes Care 2003, 26:3074–3079.

    Article  PubMed  CAS  Google Scholar 

  16. Whitehouse F, Kruger DF, Fineman M, et al.: A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 2 diabetes. Diabetes Care 2002, 25:724–730.

    Article  PubMed  CAS  Google Scholar 

  17. Ratner RE, Want LL, Fineman MS, et al.: Adjunctive therapy with the amylin analog pramlintide leads to a combined improvement in glycemic and weight control in insulin treated subjects with type 2 diabetes. Diabetes Technol Ther 2002, 4:51–61.

    Article  PubMed  CAS  Google Scholar 

  18. Chapman I, Parker B, Doran S, et al.: Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 2005, 48:838–848.

    Article  PubMed  CAS  Google Scholar 

  19. Deacon CF: Therapeutic strategies based on glucagons-like peptide 1. Diabetes 2004, 53:2181–2189. Gives a balanced appraisal of the context and therapeutic potential of GLP-1 analogues in development, including mode of action and pharmacodynamic and pharmacokinetic properties.

    Article  PubMed  CAS  Google Scholar 

  20. Vilsboll T, Holst JJ: Incretins, insulin secretion and type 2 diabetes mellitus. Diabetologia 2004, 47:357–366. A concise update of current knowledge regarding incretin hormones and the opportunities they offer for the treatment of type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  21. Xu W, Stoffers DA, Habener JF, Bonner-Weir S: Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270–2276.

    Article  PubMed  CAS  Google Scholar 

  22. De Leon DD, Deng S, Madani R, et al.: Role of endogenous glucagon-like peptide-1 in islet regeneration after partial pancreatectomy. Diabetes 2003, 52:365–371.

    Google Scholar 

  23. Nauck MA, Heimesaat MM, Behle K, et al.: Effects of glucagonlike peptide 1 on the counterregulatory hormone responses, cognitive functions and insulin secretion during hyperinsulinemic stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endorcinol Metab 2002, 87:1239–1246.

    Article  CAS  Google Scholar 

  24. Degn KB, Brock B, Juhl CB, et al..: Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 2004, 53:2397–2403.

    Article  PubMed  CAS  Google Scholar 

  25. Zander M, Madsbad S, Madsen JL, Holst JJ: Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002, 359:824–830.

    Article  PubMed  CAS  Google Scholar 

  26. Vella A, Shah P, Reed AS, et al.: Lack of effect of exendin-4 and glucagon-like peptide-1 (7-36) amide on insulin action in non-diabetic humans. Diabetologia 2002, 45:1410–1415.

    PubMed  CAS  Google Scholar 

  27. Kolterman OG, Buse JB, Fineman MS, et al..: Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003, 88:3082–3089.

    Article  PubMed  CAS  Google Scholar 

  28. Kendall DM, Riddle MC, Rosenstock J, et al.: Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005, 28:1083–1091.

    Article  PubMed  CAS  Google Scholar 

  29. DeFronzo RA, Ratner RE, Han J, et al.: Effects of exenatide (exendin-4) pm glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092–1100.

    Article  PubMed  CAS  Google Scholar 

  30. Chang AM, Jakobsen G, Sturis J, et al.: The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single injection. Diabetes 2003, 52:1786–1791.

    Article  PubMed  CAS  Google Scholar 

  31. Degn KB, Juhl CB, Sturis J, et al.: One week’s treatment with the long-acting glucagons-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type2 diabetes. Diabetes 2004, 53:1187–1194.

    Article  PubMed  CAS  Google Scholar 

  32. Madsbad S, Schmitz O, Ranstam J, et al.: Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagonlike peptide 1 analog liraglutide (NN2211). Diabetes care 2004, 27:1335–1342.

    Article  PubMed  CAS  Google Scholar 

  33. Kim JG, Baggio LL, Bridon DP, et al.: Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003,52:751–759.

    Article  PubMed  CAS  Google Scholar 

  34. Green BD, Gault VA, Mooney MH, et al.: Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 (7-36) amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003, 31:529–540.

    Article  PubMed  CAS  Google Scholar 

  35. Green BD, Irwin N, Gault VA, et al.: Development and therapeutic potential of incretin hormone analogues for type 2 diabetes. Br J Diabetes Vasc Dis 2005, 5:134–140.

    Article  CAS  Google Scholar 

  36. Joseph JW, Kalitsky J, St-Pierre S, Brubaker PL: Oral delivery of glucagon-like peptide-1 in a modified polymer preparation normalises basal glycaemia in diabetic db/db mice. Diabetologia 2000, 43:1319–1328.

    Article  PubMed  CAS  Google Scholar 

  37. Drucker DJ: Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003, 12:87–100. Comprehensive evaluation of the potential therapeutic applications of dipeptidyl peptidase inhibition as a potential new approach to the treatment of type 2 diabetes.

    Article  PubMed  CAS  Google Scholar 

  38. Morimoto C, Schlossman SF: The structure and function of CD26 in the T-cell immune response. Immunol Rev 1998, 161:55–70.

    Article  PubMed  CAS  Google Scholar 

  39. Marguet D, Baggio L, Kobayashi T, et al.: Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U S A 2000, 97:6874–6879.

    Article  PubMed  CAS  Google Scholar 

  40. Hansotia T, Baggio LL, Del Meire D, et al.: Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors. Diabetes 2004, 53:1326–1335.

    Article  PubMed  CAS  Google Scholar 

  41. Weber AE: Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 2004, 47:4135–4141.

    Article  PubMed  CAS  Google Scholar 

  42. Deacon CF, Ahren B, Holst JJ: Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004, 13:1091–1102. Thorough appraisal of current knowledge on use of DPP-IV inhibitors in preclinical and clinical development.

    Article  PubMed  CAS  Google Scholar 

  43. Mest HJ, Mentlein R: Dipeptidyl peptidase inhibitors as new drugs for the treatment of type 2 diabetes. Diabetologia 2005, 48:616–620.

    Article  PubMed  CAS  Google Scholar 

  44. Pratley RE, Gomis R, Standl E, et al.: Long-term efficacy of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes inadequately treated with metformin. Diabetologia 2004, 47(suppl 1):A69-A70.

    Google Scholar 

  45. Ahren B, Landin-Olsson M, Jansson PA, et al.: Inhibition of dipeptidyl peptidase-4 reduces glycemia sustains insulin levels and reduces glucagons levels in type 2 diabetes. J Clin Endocrinol Metab 2004, 89:2079–2084.

    Article  CAS  Google Scholar 

  46. Herman GA, Zhao PL, Dietrich B, et al.: The DPP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetes. Diabetologia 2004, 47(suppl 1):A287.

    Google Scholar 

  47. Lindsay JR, Duffy NA, McKillop AM, et al.: Inhibition of dipeptidyl peptidase IV activity by oral metformin in type 2 diabetes. Diabetic Med 2005, 22:654–657.

    Article  PubMed  CAS  Google Scholar 

  48. Deacon CF, Plamboeck A, Holst JJ, Carr RD: Neutral endopeptidase 24.11 inhibition improves glucose tolerance in anaesthetized pigs independently of effects on active glucagon-like peptide-1. Diabetologia 2004, 47(suppl 1):A282.

    Google Scholar 

  49. Berger JP, Akiyama TE, Meinke PT: PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005, 26:244–251. Excellent general review of therapeutic prospects for PPAR agonists.

    Article  PubMed  CAS  Google Scholar 

  50. Yki-Jarvinen H: Thiazolidinediones. N Engl J Med 2004, 351:1106–1118.

    Article  PubMed  Google Scholar 

  51. Bailey CJ: New pharmacologic agents for diabetes. Curr Diab Rep 2001, 1:119–126.

    PubMed  CAS  Google Scholar 

  52. Chapman MJ: Fibrates in 2003: therapeutic action in atherogenic dyslipidaemia and future perspectives. Atherosclerosis 2003, 171:1–13.

    Article  PubMed  CAS  Google Scholar 

  53. Cronet P, Petersen JFW, Folmer R, et al.: Structure of the PPAR-alpha and -gamma ligand binding domain in complex with AZ242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9:699–706.

    Article  PubMed  CAS  Google Scholar 

  54. Ljung B, Bamberg K, Dahllof B, et al.: AZ242, a novel PPARalpha/ gamma agonist with beneficial effects in insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J Lipid Res 2002, 43:1855–1863.

    Article  PubMed  CAS  Google Scholar 

  55. Harrity T, Chu C, Kunselman L, et al.: Muraglitazar, a novel non-TZD dual PPARalpha/gamma agonist, improves metabolic abnormalities in obese, severely diabetic db/db mice. Diabetes 2004, 53(suppl 2):A31-A32.

    Google Scholar 

  56. Barlocco D: Muraglitazar. Curr Opin Investig Drugs 2005, 6:427–434.

    PubMed  CAS  Google Scholar 

  57. Mohideen P, Prill VD, Rubin CJ: Glycemic efficacy and safety of muraglitazar, a novel dual PPARalpha/gamma agonist, plus glyburide inpatients with type 2 diabetes failing sulfonylurea monotherapy: a randomized double blind-placebo controlled study. Diabetes 2005, 54(suppl 1):A128.

    Google Scholar 

  58. DeFronzo RA, Rubin CJ, Mohideen P, et al.: Improvement of glycemic control with muraglitazar a novel dual PPARalpha/ gamma agonist, in combination with metformin in patients with type 2 diabetes: double-blind randomised pioglitazone controlled study. Diabetes 2005, 54(suppl 1):A4.

    Google Scholar 

  59. Wang YX, Lee CH, Tiep S, et al.: Peroxisome-proliferator activated receptor delta activates fat metabolism to prevent obesity. Cell 2003, 113:159–170.

    Article  PubMed  CAS  Google Scholar 

  60. Evans RM, Barish GD, Wang YX: PPARs and the complex journey to obesity. Nat Med 2004, 10:1–7. Valuable perspective on the role and therapeutic implications of PPAR-δ.

    Article  CAS  Google Scholar 

  61. Oliver W, Wilson J, Winegar D, et al.: A PPAR pan agonist delivers glycemic control and improved lipid profiles without weight gain and hemodilution in rodent models of type 2 DM, dyslipidemia and obesity. Diabetes 2003, 52(suppl 1):A453.

    Google Scholar 

  62. Liu Y, Sennitt MV, Hislop DC, et al.: Retinoid X receptor agonists have anti-obesity effects and improve insulin sensitivity in Zucker fa/fa rats. Int J Obes 2000, 24:997–104.

    Article  CAS  Google Scholar 

  63. Cha BS, Ciaraldi TP, Carter L, et al.: Peroxisome proliferator-activated receptor (PPAR)gamma and retinoid X receptor (RXR) agonists have complimentary effects on glucose and lipid metabolism in skeletal muscle. Diabetologia 2001, 44:444–452.

    Article  PubMed  CAS  Google Scholar 

  64. Yamauchi T, Waki H, Kamon J, et al.: Inhibition of RXR and PPARgamma ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 2001, 108:1001–1013.

    Article  PubMed  CAS  Google Scholar 

  65. Di Marzo V, Bifulco M, De Petrocellis L: The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 2004, 3:771–784. Insight into new opportunities for agents to modulate the endogenous cannabinoid system.

    Article  CAS  Google Scholar 

  66. Di Marzo V, Goparaju SK, Wang L, et al.: Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001, 410:822–825.

    Article  Google Scholar 

  67. Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:423–431. Preclinical study showing reduced food intake and reduced fat mass in CB1 receptor-deficient mice.

    Article  PubMed  CAS  Google Scholar 

  68. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effect of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lepob/ Lepob mice. Int J Obes 2005, 29:183–187.

    Article  CAS  Google Scholar 

  69. Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389–1397.

    Article  PubMed  CAS  Google Scholar 

  70. Scheen AJ, et al.: Rimonabant in patients with type 2 diabetes: results from the RIO-Diabetes trial. Late-breaking clinical trials. itPaper presented at the 65th Annual Scientific Sessions of the American Diabetes Association. San Diego, CA; June 10–14, 2005.

  71. Bailey CJ, Day C: New pharmacological approaches to obesity. Obesity in Practice 2005, 1:2–5.

    Google Scholar 

  72. Bailey CJ: New drugs for the treatment of diabetes mellitus. In International Textbook of Diabetes Mellitus, edn 3. Edited by DeFronzo RA, et al. Chichester: Wiley Publishers; 2004:951–979. General coverage of new approaches for the treatment of diabetes.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Group, Life and Health Sciences, Aston University, B4 7ET, Aston Triangle, Birmingham, UK

    Clifford J. Bailey PhDFRCP, FRCPath

Authors
  1. Clifford J. Bailey PhDFRCP, FRCPath
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bailey, C.J. Drugs on the horizon for diabesity. Curr Diab Rep 5, 353–359 (2005). https://doi.org/10.1007/s11892-005-0093-1

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11892-005-0093-1

Keywords

Search

Navigation